PTAB invalidates Prevnar 13 patent

14-03-2019

PTAB invalidates Prevnar 13 patent

photobyphm / Shutterstock.com

American pharmaceutical company Merck & Co. has secured a victory against its rival Pfizer in an inter partes review of a patent concerning Prevnar 13, the biggest-selling vaccine in the world.


Merck & Co., Pfizer, Prevnar 13, vaccine, pneumonia, patent invalidation, Patent Trial and Appeal Board, prior art

LSIPR